BioSpace News Archive

IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced today it will present a poster at the upcoming International Neuroscience Conference of the Federation of the European Neuroscience Societies (FENS).

A New Business Strategy report released by Data Bridge Market Research with the title Global Internet of Medical Things (IoMT) Market Study Forecast till 2028.

Bolden Therapeutics, Inc. announced being awarded a Small Business Innovative Research grant for $497,500 from the National Institute on Aging of the National Institutes of Health.

ANGLE plc, a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier, all resolutions were duly passed.

A New Business Strategy report released by Data Bridge Market Research with the title Global Active Pharmaceutical Ingredients (API) Market Study Forecast till 2028.

Eurofins DiscoverX announced the official opening of its new China biotechnology office in Shanghai.

AION Labs, Israel -based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), seeks global research talent for new startup focused on: “Prediction of Clinical Trial Outcome in Biomarker-Stratified Cancer Patient Populations”

BioMech Health, a division of BioMech Holdings, LLC which provides clinically actionable solutions to improve health, quality of life and performance, announced that it has received the award for “Best Overall Biometric Solution” in the fifth annual AI Breakthrough Awards.

Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company’s board of directors, effective July 1, 2022.

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the initiation of its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.